• 3:00-3:30 PM Networking & Registration
• 3:30-5:00 PM Venture Capital Panel
• 5:00-6:30 PM Networking Reception & Champagne Holiday Celebration
Effectively raising capital is crucial for any company. The first key to get funding is to understand where the money is. Join experts from the Investment world to understand the types of financings that are occurring in your industry today– including topics such as who is getting funding, current valuations and other terms, what investors are looking for, etc. – and what is new and what to expect for 2006.
• Kevin Wasserstein
, Principal, Versant Ventures
• Andrew Farquharson
, Kauffman Fellow, The Angel's Forum
• Nancy Kamei
, Manager, Intel Capital
• Charles Hsu
, Venture Partner, AM Pappas Ventures
• John Steuart
, Managing Director, Claremont Creek Ventures
• Steve Bengston
, Founding Sponsor, PricewaterhouseCoopers
• Paul M. Grand
, Director, RCT BioVentures Pacific Coast Office
Kevin Wasserstein, Principal, Versant Ventures
Kevin Wasserstein specializes in investing and building early-stage medical device companies, and is actively involved with several of Versant’s portfolio companies and affiliations, including: Liposonix, NeoGuide Systems, Rox Medical, Second Sight Medical and The Innovation Factory. Kevin joined Versant with more than ten years of successful operating roles in medical device and high technology companies, most recently serving in a variety of marketing and business development roles at Guidant Corporation. During his tenure at Guidant, Kevin acted as the Director of Marketing in Guidant’s Cardiac Surgery Group, managing product development and launch initiatives and spearheading market development programs to drive adoption of minimally invasive cardiac surgery. Kevin also served as Senior Global Product Manager in Guidant’s Peripheral and Carotid Group, during which he developed and launched several first-generation stent and embolic protection devices. Previously, in Guidant’s Compass Business Development Group, Kevin was involved in acquisition, licensing and investment activities with both private and public medical device companies, and in formulating corporate strategies to develop innovative medical technologies. Kevin’s operational experience also includes business development at Heartstream and engineering design and engineering management responsibilities at Hughes Aircraft Company. Kevin holds Bachelor’s and Master’s degrees in Mechanical Engineering, as well as an MBA, all from Stanford University.
Andrew Farquharson, Kauffman Fellow, The Angel's Forum
Andrew Farquharson is an early-stage investor in life sciences, who brings 14 years of experience as a founder, executive and researcher in the biotherapeutic, genomic and proteomic arenas. He is currently a Kauffman Fellow with the Halo Fund, and Chairman of Ergodesigns, Inc., which he founded in 2003.
In his earlier career, Mr. Farquharson served as Vice President of Commercial Operations for Innovadyne Technologies, a laboratory automation start-up that he helped to build into a profitable concern by growing sales in HTS and proteomic markets. Prior to Innovadyne, Mr. Farquharson served as Senior Vice President of sales and marketing for QIAGEN Operon, where he tripled revenues of synthetic DNA products in two years, and played a key role in negotiating a sale of the business for nine figures. In his earlier career, Mr. Farquharson held several roles in research operations at Genentech, Inc. and co-founded a gene design business in agricultural biotechnology. He has also developed strategies for healthcare firms as a consultant.
Mr. Farquharson received a BA with High Honors from the University of California at Berkeley, and his Masters of Business Administration from Harvard University Graduate School of Business.
Nancy Kamei, Manager, Intel Capital
Nancy Kamei is responsible for investments in the Biomedical and Life Sciences industries. Prior to joining Intel Capital, Nancy was responsible for investments in public securities in the biotechnology and healthcare industries at Capital Group Companies. Nancy began her career in operating roles in the pharmaceutical and biotechnology industries. She has a PharmD degree from UCSF School of Pharmacy and an MBA from Stanford.
Charles Hsu, Venture Partner, AM Pappas Ventures
Charles has been an active venture capital investor since 1990. He was a General Partner of the Walden Group or its affiliate, Walden International, from early 1996 through early 2003. Prior to joining Walden, he co-managed life sciences investments at Advent International, a global private equity firm based in Boston. He has served as a lead investor or board member for more than 25 life science and healthcare companies, and he was a founding investor of Ribozyme Pharmaceuticals (IPO in 1996). Some of his other realized investments include Aviron (IPO in 1996, later acquired by MedImmune); KOSAN Biosciences Inc. (IPO in 2000); and Lexicon Genetics (IPO in 2000). AMP&A; has worked closely with Charles on several investments, including its current portfolio company Plexxikon.
In addition to his AMP&A; fund management responsibilities,Charles is a director of Asia Renal Care, the leading independent dialysis services company in Asia, of which he was a co-founding investor, and he is Chairman of Eureka! Pharmaceuticals, a privately-held life sciences company based in San Francisco and Shanghai.
Education: Charles holds an AB in Biochemistry from Harvard University, an MBA from Stanford University and a Ph.D. also from Stanford University.
John Steuart, Managing Director, Claremont Creek Ventures
John Steuart has enjoyed a 20 year career in company finance and operations as well as venture investing. He was COO of Cybergold from its founding through its successful IPO when he made the transition to CFO of the combined Mypoints/Cybergold entity. Mr. Steuart was also with Alafi Capital as an officer of the General Partner. Alafi Capital is a Berkeley-based private venture capital firm which concentrates on seed and early stage companies in the biomedical and biotechnological arenas. Prior Alafi investments include: Amgen, Biogen, Cetus (acquired by Chiron), Applied Biosystems, Molecular Devices and Qiagen. Mr. Steuart has also served in early stage management and as a board director in over a dozen successful start-ups. He is particularly interested in opportunities in IT applied to the life sciences and medical care.
Steve Bengston, Founding Sponsor, PricewaterhouseCoopers
Steve is Managing Director of Emerging Company Services (ECS) at PricewaterhouseCoopers. ECS acts as “mentor capitalists” for young, high potential companies. ECS works closely with the leading opinion leaders/influencers in the Bay Area, including venture capitalists, attorneys, bankers and other service providers that have made Silicon Valley the leading high tech center in the world.
Before joining PwC, Steve had 20 years of experience in a variety of marketing, business development and general management roles at several high tech companies in the Bay Area. Most recently, he was Pres/CEO of ynot.com, a leading international e-marketing and greeting card company. Previously, he was VP Marketing & Business Development at Worldview Systems, an Internet travel pioneer. At Worldview, Steve helped launch and market Travelocity with Sabre Interactive.
Steve has a BA in Economics and MBA from Stanford University. He works closely or sits on the Advisory Board at SVASE, SDForum, Financing Partners, and the Stanford/MIT Venture Lab, has taught classes on funding/running start ups at UC Berkeley, Santa Clara Law School, Hastings Law School, and Stanford, and is active in a variety of other organizations in the Bay Area targeting entrepreneurs and investors. He is a frequent moderator/panelist at both university and industry sponsored events.
Paul M. Grand Director, RCT BioVentures Pacific Coast Office
Grand represents RCT and the RCT BioVentures early-stage investment program to start-up companies and research institutions on the west coast of the United States. He has built, operated, recruited management and rose financing for eight high technology, medical device and biotechnology companies.